The "Biomarker Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 509 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of biomarker deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.

The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The initial chapters of this report provide an orientation of biomarker dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in biomarker dealmaking since 2016.

Chapter 3 provides an overview of the leading biomarker deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of biomarker deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2016. The chapter is organized by specific biomarker technology type in focus.

Key Benefits

• Understand deal trends since 2016
• Browse biomarker collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report Scope

• Trends in biomarker dealmaking in the biopharma industry
• Directory of biomarker deal records covering pharmaceutical and biotechnology
• The leading biomarker deals by value
• Most active biomarker licensing dealmakers

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

2.1. Introduction

2.2. Biomarker deals over the years

2.3. Most active biomarker dealmakers

2.4. Biomarker deals by deal type

2.5. Biomarker deals by therapy area

2.6. Biomarker deals by industry sector

2.7. Deal terms for biomarker deals

2.7.1 Biomarker deals headline values

2.7.2 Biomarker deal upfront payments

2.7.3 Biomarker deal milestone payments

2.7.4 Biomarker royalty rates

Chapter 3 - Leading biomarker deals

3.1. Introduction

3.2. Top biomarker deals by value

Chapter 4 - Most active biomarker dealmakers

4.1. Introduction

4.2. Most active biomarker dealmakers

4.3. Most active biomarker deals company profiles

Chapter 5 - Biomarker contracts dealmaking directory

5.1. Introduction

5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

Deal directory

• Deal directory - Biomarker deals by company A-Z
• Deal directory - Biomarker deals by deal type
• Deal directory - Biomarker deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/mmvruh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710174662/en/